Opelz Gerhard, Zeier Martin, Laux Gunter, Morath Christian, Döhler Bernd
Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
J Am Soc Nephrol. 2006 Nov;17(11):3257-62. doi: 10.1681/ASN.2006050543. Epub 2006 Oct 11.
It was reported recently that treatment of kidney transplant recipients with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type 1 receptor blockers (ARB) is associated with strikingly improved long-term graft and patient survival. This finding has important implications for future posttransplantation therapy recommendations. In an analysis of 17,209 kidney and 1744 heart transplant recipients, an association of treatment with ACEI/ARB with improved transplant outcome could not be confirmed. It is concluded that recommendations for a widespread use of ACEI/ARB treatment in transplant recipients are unwarranted.
最近有报道称，用血管紧张素转换酶抑制剂（ACEI）或1型血管紧张素II受体阻滞剂（ARB）治疗肾移植受者与显著改善长期移植物和患者生存率相关。这一发现对未来移植后治疗建议具有重要意义。在一项对17209例肾移植受者和1744例心脏移植受者的分析中，无法证实ACEI/ARB治疗与改善移植结局之间的关联。得出的结论是，在移植受者中广泛使用ACEI/ARB治疗的建议是没有根据的。
